The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles
Artikel i vetenskaplig tidskrift, 2026
When introduced into biological systems, the function and biodistribution of lipid nanoparticles (LNPs) are affected by the biomolecular coronas they acquire. Corona composition is determined by the biophysical and chemical properties of the particles and the contents of the biofluids. Polyethylene glycol (PEG) polymers, anchored using lipids that partition into LNPs during formulation, are key to LNP stability in circulation. It is, however, not well-studied how different PEG-lipid anchors, with different acyl chain lengths, headgroup/linker chemistries, and desorption rates (PEG "shedding" from nanoparticles) can affect corona composition and LNP function. Here, we examined how common PEG-lipid anchors affect (1) in vivo biodistribution in C57BL/6 mice, (2) corona content (using mass spectrometry-based proteomics), (3) LNP biophysical characteristics (using single-particle automated Raman trapping analysis (SPARTA (R))), and (4) in vitro particle function (using cellular uptake and cargo delivery assays). Following nanoparticle formulation with clinically approved, commonly used PEG anchors, we found that the LNP biodistribution is strongly impacted, particularly in the liver, spleen, bone marrow, and lung. We then tested a wide range of lipid ratio combinations using high-throughput evaluation in vitro. Despite being minor LNP components (by molar ratio), the PEG-lipid anchors strongly impact the chemical characteristics, corona content, and particle function. These findings reveal structure-activity relationships between PEG-lipid anchor chemistry and functional LNP biodistribution, with implications for rational LNP design.
Raman spectroscopy
lipidchemistry
polyethylene glycol
lipid nanoparticle
mass spectroscopy
protein corona
Författare
Chuan-En Lu
AstraZeneca AB
Kai Liu
AstraZeneca AB
Audrey Gallud
AstraZeneca AB
Viktoriia Meklesh
AstraZeneca AB
Lisbeth Thorup Ravnkilde
AstraZeneca AB
Juna Santos
AstraZeneca AB
Filipa Dias Louro
AstraZeneca AB
Tasso Miliotis
AstraZeneca AB
Marco A. Alfonzo-Mendez
AstraZeneca AB
Joanna Rejman
AstraZeneca AB
Luca Panariello
Karolinska Institutet
Hanna M. G. Barriga
Kungliga Tekniska Högskolan (KTH)
Karolinska Institutet
Molly M. Stevens
University of Oxford
Karolinska Institutet
Fredrik Höök
Chalmers, Fysik
Marianna Yanez Arteta
AstraZeneca AB
Johan Ulander
AstraZeneca AB
Suzy Jones
AstraZeneca AB
Alan Sabirsh
AstraZeneca AB
ACS Nano
1936-0851 (ISSN) 1936-086X (eISSN)
Vol. In PressÄmneskategorier (SSIF 2025)
Medicinsk bioteknologi
Farmaceutiska vetenskaper
Fysikalisk kemi
DOI
10.1021/acsnano.5c19757
PubMed
41845897